Price Behavior of Originator Adalimumab After Biosimilars Entry: Evidence From the Colombian Market
Author(s)
Yesith Toloza, MSc1, Wilmer Rojas, MSc2, Carolina Becerra, MSc3, Jorge Donado, MSc1, NATALIA A. DUQUE, Master4, Oscar Díaz, MSc1.
1Medicarte, Medellin, Colombia, 2Medicarte, MEDELLIN, Colombia, 3Medicarte, Bucaramanga, Colombia, 4ASISTENTE, Medicarte, Medellin, Colombia.
1Medicarte, Medellin, Colombia, 2Medicarte, MEDELLIN, Colombia, 3Medicarte, Bucaramanga, Colombia, 4ASISTENTE, Medicarte, Medellin, Colombia.
OBJECTIVES: To assess the price evolution of originator adalimumab following the entry of biosimilars in Colombia.
METHODS: A retrospective analysis was conducted using data from Colombia’s Drug Price Information System (SISMED). Information was collected on dispensed volumes and unit price ranges for the originator adalimumab (Humira®). Biosimilars (Amgevita®, Idacio®, and Hyrimoz®) were included from their respective market entry dates. Weighted average prices were calculated annually based on dispensed units, and all prices were standardized by estimating cost per milligram to ensure comparability. All prices were deflated to 2024 values and subsequently converted to US dollars using the representative market exchange rate from 31/12/24 (1 USD = 4,409 COP). A joinpoint regression was conducted, and the Annual Percent Change (APC) was calculated to identify significant changes and overall price dynamics over time.
RESULTS: Between 2015-2019, the APC of Humira® was 0.29%, with an average price of 7.4 USD/mg. After the entry of biosimilars and four years of market competition, the APC decreased to -8.90%, reaching 4.4 USD/mg. Amgevita®, the first biosimilar launched in Colombia in 2019, entered the market at 9.72 USD/mg and steadily declined to 3.4 USD/mg by 2024. It exhibited the most pronounced annual decline, with an APC of -23.26%. Hyrimoz® and Idacio®, both introduced in 2022, showed APCs of -10.91% and -16.48%, respectively. By 2024, both were priced below 1.5 USD/mg. All APC estimates were statistically significant (p<0.05).
CONCLUSIONS: Prices of originator adalimumab declined steadily after biosimilar entry, with similar trends observed for biosimilars. These findings suggest that biosimilar competition contributes to cost containment and plays a key role in improving access and promoting sustainability within the colombian health system.
METHODS: A retrospective analysis was conducted using data from Colombia’s Drug Price Information System (SISMED). Information was collected on dispensed volumes and unit price ranges for the originator adalimumab (Humira®). Biosimilars (Amgevita®, Idacio®, and Hyrimoz®) were included from their respective market entry dates. Weighted average prices were calculated annually based on dispensed units, and all prices were standardized by estimating cost per milligram to ensure comparability. All prices were deflated to 2024 values and subsequently converted to US dollars using the representative market exchange rate from 31/12/24 (1 USD = 4,409 COP). A joinpoint regression was conducted, and the Annual Percent Change (APC) was calculated to identify significant changes and overall price dynamics over time.
RESULTS: Between 2015-2019, the APC of Humira® was 0.29%, with an average price of 7.4 USD/mg. After the entry of biosimilars and four years of market competition, the APC decreased to -8.90%, reaching 4.4 USD/mg. Amgevita®, the first biosimilar launched in Colombia in 2019, entered the market at 9.72 USD/mg and steadily declined to 3.4 USD/mg by 2024. It exhibited the most pronounced annual decline, with an APC of -23.26%. Hyrimoz® and Idacio®, both introduced in 2022, showed APCs of -10.91% and -16.48%, respectively. By 2024, both were priced below 1.5 USD/mg. All APC estimates were statistically significant (p<0.05).
CONCLUSIONS: Prices of originator adalimumab declined steadily after biosimilar entry, with similar trends observed for biosimilars. These findings suggest that biosimilar competition contributes to cost containment and plays a key role in improving access and promoting sustainability within the colombian health system.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE615
Topic
Economic Evaluation, Epidemiology & Public Health, Real World Data & Information Systems
Disease
Biologics & Biosimilars, Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal), Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)